Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2024-10-29 Regulatory Filings
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
Pharmanutra: Accordo con Advisor Internazionale per il piano di sviluppo di PharmaNutra USA
Regulatory Filings Classification · 1% confidence The document is an official communication from Pharmanutra S.p.A. dated October 29, 2024, identified by the header "Informazione Regolamentata n. 20106-43-2024" and the object "Pharmanutra: Accordo con Advisor Internazionale per il piano di sviluppo di PharmaNutra USA". The content details the signing of an agreement with an international strategic consulting firm to define the development plan for its US subsidiary. This type of announcement, which communicates a significant business development or strategic step outside of routine financial reporting (like earnings or annual reports), typically falls under general regulatory announcements or specific strategic updates. Since it is not a formal financial report (10-K, IR, ER), a management discussion (MDA), or a capital event (CAP, SHA), and it is a specific business update, it best fits the general category for regulatory announcements that don't fit elsewhere, which is RNS (Regulatory Filings). It is not an announcement of a report publication (RPA) because it is the substance of the news itself, not just a notice that a report is available. Given the context of Italian regulated information ('Informazione Regolamentata'), RNS is the most appropriate catch-all for material, non-standardized corporate news.
2024-10-29 Italian
Allegato 3F - Settembre 2024
Transaction in Own Shares Classification · 1% confidence The document is titled 'SCHEMA DI COMUNICAZIONE DELLE OPERAZIONI SUI TITOLI DELL'EMITTENTE' (Disclosure Form for Transactions in the Issuer's Securities) and specifically details transactions conducted by a party ('INTERMONTE SPA') involving the issuer's shares (PHARMANUTRA) during the reference period 09/2024. Section 2 details daily transactions (date, quantity, price) and a period summary. Section 3 discusses the program for the purchase and sale of treasury shares. This structure strongly indicates a mandatory disclosure filing related to insider transactions or significant share dealings, which aligns with the 'Director's Dealing' (DIRS) or potentially 'Transaction in Own Shares' (POS) if the transactions were by the company itself. Since the transaction is detailed by a third party ('INTERMONTE SPA') regarding the issuer's securities, and the form is a standardized regulatory disclosure schema for transactions in issuer securities, it most closely matches the scope of insider/director dealing disclosures, even if the reporting party isn't explicitly a director in the visible text, as these forms are used for reporting significant transactions by related parties. However, the presence of Section 3 regarding the 'PROGRAMME FOR THE PURCHASE AND SALE OF TREASURY SHARES' suggests a focus on share repurchase/issuance activity by the company itself, which points towards POS. Given the detailed breakdown of transactions (Section 2) and the context of regulatory disclosure ('Informazione Regolamentata'), the most precise fit among the options for reporting transactions in own shares or significant related party transactions is POS (Transaction in Own Shares) or DIRS (Director's Dealing). Since the document details transactions by a specific party (INTERMONTE SPA) and not just the company's own buyback program (though Section 3 is present), and it is a formal regulatory disclosure schema, DIRS is a strong candidate if INTERMONTE is an insider. However, POS specifically covers the company buying back or selling its own shares. Given the ambiguity and the presence of both elements, I will prioritize the specific transaction reporting schema which often covers insider/director transactions (DIRS) or the general category for share transactions (POS). Since the document is a formal regulatory disclosure ('Informazione Regolamentata') detailing transactions in the issuer's securities, and the structure is highly specific, it is a mandatory filing. If the transactions were by directors/executives, it's DIRS. If it's about the company's treasury stock program, it's POS. The presence of Section 3 strongly suggests POS is relevant, but Section 2 details transactions by 'INTERMONTE SPA'. In many jurisdictions, these forms cover insider transactions. Given the options, DIRS covers personal share transactions by directors/executives, and POS covers the company buying back/selling its own shares. Without confirmation of INTERMONTE's role, DIRS is often the category for mandatory transaction disclosures by related parties. However, the form structure is very similar to mandatory transaction reports. I will classify it as DIRS as it reports transactions in securities by a specific entity, which is the core of DIRS, rather than just the company's general treasury activity (POS).
2024-10-02 Italian
Presentazione - Le Eccellenze del Made in Italy - Milano, 25 Settembre 2024
Investor Presentation Classification · 1% confidence The document is a comprehensive slide deck titled 'PHARMANUTRA GROUP' dated September 2024. It contains detailed financial performance data (2024 First Half results), historical financial tables, market position analysis, R&D updates, and strategic growth drivers. It is clearly designed for investors to review the company's business strategy and financial health. Given the structure, content, and purpose, it is classified as an Investor Presentation. H1 2024
2024-09-25 English
First-Half Financial Report as at 30 June 2024
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM MANAGEMENT REPORT' and explicitly states it is the 'First half financial report' for the period ended 30 June 2024. It contains comprehensive financial statements, including the consolidated balance sheet, income statement, and explanatory notes, as well as management's discussion and analysis of the group's performance. It is a full financial report for a period shorter than a fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2024
2024-09-13 English
Relazione Finanziaria Semestrale al 30 giugno 2024
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RESOCONTO INTERMEDIO DI GESTIONE RELAZIONE FINANZIARIA SEMESTRALE' (Interim Management Report - Half-Yearly Financial Report) for the period ending June 30, 2024. It contains comprehensive financial statements, consolidated balance sheets, income statements, and explanatory notes for the PharmaNutra Group. As it is a full interim financial report containing substantive financial data and analysis rather than just an announcement or certification, it is classified as an Interim/Quarterly Report. H1 2024
2024-09-13 Italian
Deposito della Relazione Finanziaria Semestrale || Filing of the First-Half Financial Report
Report Publication Announcement Classification · 1% confidence The document is an official announcement titled 'Deposito della Relazione Finanziaria Semestrale' (Filing of the First-Half Financial Report) for the period ending June 30, 2024. This explicitly states that the 'Relazione Finanziaria Semestrale' (First-Half Financial Report) is now available to the public at various locations, including the company website and storage mechanism. Since the document itself is an announcement stating the report is available, and it is not the comprehensive report itself, it fits the definition of a Report Publication Announcement (RPA). The length (8115 chars) is substantial but the content is purely an announcement of availability, not the detailed financial statements typical of an Interim Report (IR).
2024-09-13 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.